New Study Reveals Unlikely Beneficiaries of Invasive Species: Major Pharmaceutical Corporations
A newly published analysis is raising eyebrows after revealing that some of the world’s largest pharmaceutical companies have been quietly funding research into the proliferation of certain invasive species, specifically zebra mussels and Asian carp, in North American waterways. While mainstream environmental groups focus on the ecological damage, critics point to a complex web of patents and profit. Pharmaceutical giants have been filing patents for unique compounds extracted from these species’ proteins, claiming they can treat everything from chronic inflammation to antibiotic-resistant infections. Environmental journalist Patricia Moore, who authored the report, asks: “When an invasive species is framed solely as a crisis, who has the most to gain from a never-ending supply of raw biological material?” The patents, some dating back a decade, suggest a strategy where maintaining the ‘pest’ status of these species ensures a steady, unregulated harvest—and a lucrative new ‘natural resource’ for the medical industry.